Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NCT03278626
Terminated
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: University of Califonia, San Diego, La Jolla, California +4 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
NCT03486314
Completed
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Neoplasm
Register for Updates
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
NCT02810457
Completed
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2022
Locations: Research Site 7814 - Compassionate Care Research Group, Fountain Valley, California +146 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
NCT02978716
Terminated
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for participants with metastatic triple negative breast cancer. The study was an open-label and 102 participants were randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups: * Group 1: GC therapy (Days 1 and 8 of 21-day cycle... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2022
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +53 locations
Conditions: Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
Register for Updates
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
NCT00193427
Completed
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2022
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
NCT00393068
Completed
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer. Side effects (toxicity) information will also be collected.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2022
Locations: Florida Cancer Specialists, Fort Myers, Florida +8 locations
Conditions: Esophageal Cancer
Register for Updates
Pembro/Carbo/Taxol in Endometrial Cancer
NCT02549209
Completed
This is a single-arm, open-label, multi-center phase II study for subjects with measurable advanced or recurrent endometrial cancer using pembrolizumab in combination with carboplatin and paclitaxel chemotherapy. As this combination of agents has not been tested in this subject population, the first six subjects enrolled will constitute a safety run-in cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Ironwood Cancer and Research Centers, Mesa, Arizona +5 locations
Conditions: Endometrial Cancer, Endometrial Adenocarcinoma
Register for Updates
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
NCT03067610
Completed
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/16/2022
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
Register for Updates
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
NCT04470674
Withdrawn
This is a two arm, randomized, phase II study of patients with advanced KRAS mutation positive and PD-L1 high NSCLC who have not received therapy for advanced stage disease. Patients will be randomized between Arm A and Arm B treatment. Arm A treatment will consist of durvalumab every 4 weeks for 13 cycles. Arm B treatment will consist of durvalumab with chemotherapy every 3 weeks for 4 cycles followed by durvalumab with pemetrexed every 3 weeks for 13 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Register for Updates
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
NCT04832438
Withdrawn
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \[ACC\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2022
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms
Register for Updates
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096200
Completed
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/13/2022
Locations: Moffitt Cancer Center at Tampa General Hospital, Tampa, Florida +4 locations
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
NCT00867178
Completed
This pilot clinical trial studies the side effects and the best way to give vorinostat with isotretinoin and combination chemotherapy and to see how well they work in treating younger patients with embryonal tumors of the central nervous system. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as isotretinoin, vincristine sulfate, cisplatin, cyclophosphamide, and etoposide phosphate, work in different ways to s... Read More
Gender:
ALL
Ages:
Between 2 months and 47 months
Trial Updated:
01/12/2022
Locations: Children's Hospital Los Angeles, Los Angeles, California +14 locations
Conditions: Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Register for Updates